Roy M. "Trip" Gulick, MD, MPH 2004 conflict of interest/competing interest disclosures for Roy M. “Trip” Gulick From the DHHS treatment guidelines (10/29/2004) Abbott Labs: Research Ad-hoc consultant Agouron: Ad-hoc consultant† Boehringer-Ingelheim: Ad hoc consultant Bristol-Myers Squibb: Ad hoc consultant, speaker honoraria Gilead: Speaker honoraria GlaxoSmithKline: Ad-hoc consultant Merck: Speaker honoraria Panacos: Ad-hoc consultant Progenics: Research grant Pfizer: Ad-hoc consultant Pharmacia-Upjohn: Ad-hoc consultant† Roche/Trimeris: Ad hoc consultant, speaker honoraria Schering: Ad-hoc consultant Tibotec: Ad-hoc consultant Triangle: Ad-hoc consultant† Virologic: Ad-hoc consultant Source: see new Appendix A, “DHHS Panel on Clinical Practices for Treatment of HIV Infection Conflict of Interest Disclosure – October 2004,” of the DHHS “Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents” at http://www.aidsinfo.nih.gov/guidelines/adult/AA_102904.html#appendix (accessed March 26, 2005); † per 2000 disclosure From 2004 FDA transcript of the Antiviral Advisory Committee (which he chairs) Consultancy fees from two pharma companies (not identified) of less than $20,000 a year; and research funding from two pharma companies (not identified) of less than $20,000 a year (per 2004 AVAC transcript). Source: DHHS/FDA/CDER transcript, Antiviral Drugs Advisory Committee (AVAC) Meeting, Tuesday, May 13, 2003. “NDA 21-567 and 21-568, Reyataz™ (atazanavir sulfate) capsules and powder for oral use, Bristol-Myers Squibb Company, proposed for the treatment of HIV infection in combination with other antiretroviral agents”